American Journal of Psychiatry

Technology is ubiquitous in society and is now being extensively used in mental health applications. Both assessment and treatment strategies are being developed and deployed at a rapid pace. The authors review the current domains of technology ...

https://doi.org/10.1176/appi.ajp.21121254

pdf

abstract

full text

CME

SAVE ARTICLE

Articles

Targeted Oral Naltrexone for Mild to Moderate Alcohol Use Disorder Among Sexual and Gender Minority Men: A Randomized Trial

Publication date: 26 October 2022

Pages915–926

Objective: The authors sought to determine the efficacy of targeted naltrexone in sexual and gender minority men (SGM) who binge drink and have mild to moderate alcohol use disorder. Methods: In a double-blind placebo-controlled trial, a total of 120 SGM who ...

https://doi.org/10.1176/appi.ajp.20220335

Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial

Publication date: 26 October 2022

Pages927–937

Objective: Binge-eating disorder, the most prevalent eating disorder, is a serious public health problem associated with obesity, psychiatric and medical comorbidities, and functional impairments. Binge-eating disorder remains underrecognized and ...

https://doi.org/10.1176/appi.ajp.20220267

Effectiveness of Antipsychotic Use for Reducing Risk of Work Disability: Results From a Within-Subject Analysis of a Swedish National Cohort of 21,551 Patients With First-Episode Nonaffective Psychosis

Publication date: 06 October 2022

Pages938–946

Objective: The authors sought to determine whether antipsychotic use, compared with nonuse, is associated with lower work disability in first-episode nonaffective psychosis, and if so, for how long. Methods: A within-subject design was used to study the risk ...

https://doi.org/10.1176/appi.ajp.21121189

Double-Blind, Sham-Controlled Randomized Trial Testing the Efficacy of fMRI Neurofeedback on Clinical and Cognitive Measures in Children With ADHD

Publication date: 09 November 2022

Pages947–958

Objective: Functional MRI neurofeedback (fMRI-NF) could potentially be a novel, safe nonpharmacological treatment for attention deficit hyperactivity disorder (ADHD). A proof-of-concept randomized controlled trial of fMRI-NF of the right inferior frontal ...

https://doi.org/10.1176/appi.ajp.21100999

A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial

Publication date: 21 September 2022

Pages959–968

Objective: Intravenous ketamine, which displays rapid antidepressant properties, is posited to reverse depression by rapidly enhancing neuroplasticity. The authors tested whether an automated, computer-based approach could efficiently leverage enhanced ...

https://doi.org/10.1176/appi.ajp.20220216